DeepMed Research

University Hospital Antwerp

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1979-01-01

Employees: 1K

Market Cap: -

Website: http://www.uza.be

Clinical Trials

Airway Interventions During Intravenous Anesthesia in Children Undergoing Direct Laryngoscopy for Surgical Procedures Using High Flow Nasal Versus Low Flow Oxygen. a Pilot Study.(Flowkid)

Phase 4

Active, not recruiting

Conditions: Laryngoscopy
Oxygen Therapy
Child

Interventions: Device: high flow oxygen with OptiflowTM Nasal High Flow
Device: low flow oxygen with nasopharyngeal tube

First Posted Date: 2023-09-14

Last Posted Date: 2025-03-07

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 20

Registration Number: NCT06037915

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium

Dead Space in Mechanical Ventilation With Constant Expiratory Flow

Not Applicable

Recruiting

Conditions: Mechanical Ventilation
Artificial Respiration

Interventions: Device: Flow-controlled ventilation (FCV)
Device: Conventional volume-controlled ventilation (VCV)

First Posted Date: 2023-09-06

Last Posted Date: 2025-01-22

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 13

Registration Number: NCT06024993

Locations: 🇧🇪
Antwerp University Hospital (UZA), Edegem, Antwerp, Belgium

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Phase 3

Recruiting

Conditions: Acute Myocarditis

Interventions: Drug: Methylprednisolone 125 MG
Other: IV saline solution 0.9%

First Posted Date: 2023-08-03

Last Posted Date: 2025-04-17

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 174

Registration Number: NCT05974462

Locations: 🇧🇪
Universitair ziekenhuis Leuven, Leuven, Belgium
🇮🇹
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
Careggi University Hospital, Firenze, Italy

and more 16 locations

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

Phase 1

Active, not recruiting

Conditions: Ovarian Cancer
Pancreas Cancer
Esophageal Cancer
Liver Cancer

First Posted Date: 2023-07-27

Last Posted Date: 2025-04-25

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 10

Registration Number: NCT05964361

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Belgium

Long-term Evaluation of a Mobile Application for Follow-up of Cardiac Patients (Cardio2U Study)

Recruiting

Conditions: Follow-up
Mobile Health
Education

Interventions: Procedure: Cardio2U follow-up

First Posted Date: 2023-07-18

Last Posted Date: 2023-07-18

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 200

Registration Number: NCT05951088

Locations: 🇧🇪
University Hospital Antwerp, Edegem, Antwerp, Belgium

Multicenter Ventral Mesh Rectopexy Registry Collaborative

Recruiting

Conditions: Pelvic Organ Prolapse
Rectal Prolapse
Rectocele
Enterocele
Descending Perineum Syndrome
Surgery

First Posted Date: 2023-06-26

Last Posted Date: 2023-10-25

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 200

Registration Number: NCT05918367

Locations: 🇧🇪
AZ Jan Palfijn, Gent, Belgium
🇧🇪
University Hospital Antwerp, Edegem, Belgium
🇧🇪
UZ Brussel, Brussel, Belgium

and more 2 locations

Development of Artefact Removal and Physical Activity Algorithm

Recruiting

Conditions: Heart Rate
Exercise
Fitness Tracker

Interventions: Device: Wearing heart rate monitors

First Posted Date: 2023-06-13

Last Posted Date: 2023-06-13

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 138

Registration Number: NCT05901038

Locations: 🇧🇪
University Hospital Antwerp, Edegem, Antwerp, Belgium

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Phase 2

Recruiting

Conditions: Primary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis
Multiple Sclerosis

Interventions: Drug: Metformin Hydrochloride 850 mg Oral Tablet
Drug: Placebo

First Posted Date: 2023-06-07

Last Posted Date: 2024-05-10

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 120

Registration Number: NCT05893225

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Belgium
🇧🇪
Noorderhart, Overpelt, Belgium
🇧🇪
University Hospital Ghent, Ghent, Belgium

and more 2 locations

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Phase 1

Recruiting

Conditions: Malignant Pleural Mesothelioma

Interventions: Biological: Dendritic cell vaccination
Drug: Atezolizumab
Drug: Platinum/pemetrexed based chemotherapy

First Posted Date: 2023-03-13

Last Posted Date: 2024-05-16

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 15

Registration Number: NCT05765084

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Antwerp, Belgium
🇧🇪
VITAZ, Sint-Niklaas, Belgium
🇧🇪
AZ Maria Middelares, Ghent, Belgium

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Phase 4

Recruiting

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Interventions: Drug: Somatostatin analog

First Posted Date: 2023-01-27

Last Posted Date: 2024-06-14

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 270

Registration Number: NCT05701241

Locations: 🇳🇱
Amsterdam UMC, Amsterdam, North Holland, Netherlands
🇧🇪
Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium
🇳🇱
Rijnstate, Arnhem, Gelderland, Netherlands

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy